2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/04/15MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015
First Data Presentation from MyoKardia-Sponsored SHaRe Patient Registry Company Co-Founder to Deliver Prestigious Distinguished Scientist Lecture SOUTH SAN FRANCISCO, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced presentations at the American Heart Association (AHA) Scientific Sessions 2015, being held November 7-11 in Orl... 
11/03/15MyoKardia Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) today announced the closing of its initial public offering of 6,253,125 shares of common stock at a public offering price of $10.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 815,625 shares of common stock. All of the shares sold in the offering were offered by MyoKardia. The shares began trading on The NASDAQ Global Select Market under the ticker ... 
10/28/15MyoKardia Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Oct. 28, 2015-- MyoKardia, Inc. (“MyoKardia”) today announced the pricing of its initial public offering of 5,437,500 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by MyoKardia. In addition, MyoKardia has granted the underwriters a 30-day option to purchase up to an additional 815,625 shares of common stoc... 
10/14/15MyoKardia Appoints Renowned Cardiovascular Medicine Expert Eric Topol, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif. – October 14, 2015 – MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Eric J. Topol, M.D., to its board of directors and chair of the Company’s science and technology committee. Dr. Topol brings to MyoKardia more than 30 years of expertise in cardiovascular medicine and genetics. As a researcher, he has published approximately... 
10/06/15MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif. – October 6, 2015 – MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced initial clinical data from two Phase 1 trials of MYK-461, the Company’s lead product candidate, which targets the underlying cause of hypertrophic cardiomyopathy (HCM). In both trials, MYK-461 was well tolerated with dose- proportional pharmacokinetics. MYK-461 has demonstrated... 
09/30/15FierceBiotech names MyoKardia as one of its “Fierce 15” Biotech Companies of 2015
South San Francisco, CA – September 30, 2015 – MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies. MyoKardia was incorporated in 2012 by Third Rock Ventures, in partnership with world-leading scientific and clinical researchers in cardiovascular genetics and muscle biology. Since My... 
04/30/15MyoKardia, Inc. Completes $46 Million Series B Financing
SOUTH SAN FRANCISCO, Calif. – April 30, 2015 – MyoKardia, Inc., a company pioneering the development of precision therapies for genetic heart disease, today announced the successful completion of a $46 million Series B financing. Proceeds from the financing will be used to advance and expand the company’s portfolio of potential therapies for hypertrophic and dilated cardiomyopathies (HCM and DCM), including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials. The S... 
03/03/15MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif. – March 3, 2015 – MyoKardia, Inc., a company pioneering the development of precision therapies for genetic heart disease, today announced it has initiated dosing in a Phase 1 clinical trial of MYK-461. MYK-461 is the first ever therapy designed to target the underlying cause of hypertrophic cardiomyopathy (HCM), the most common heritable cardiovascular disease. Patients with HCM are born with a mutation that causes over-contraction of the heart muscle cells, leading t... 
01/07/15MyoKardia to Present at the 33rd Annual J.P. Morgan Healthcare Conference
San Francisco, Calif. – January [6], 2015 – MyoKardia, Inc., a clinical-stage biopharmaceutical company developing novel medicines to treat heritable cardiovascular diseases today announced that Tassos Gianakakos, chief executive officer, is scheduled to present a company overview and update at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 3:30 p.m. PT. The conference is being held January 12-15, 2015 at the Westin St. Francis Hotel in San Francisco. About ...